<p>A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient outcomes, according to new research from the University of British Columbia. The study, published today in <a href="https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221785"><em>CMAJ</em></a>, shows that in B.C. alone, implementing pharmacogenomic testing could save the provincial public health system an estimated $956 million over 20 years.</p>
Solving Addiction to Gambling – THISDAYLIVE thisdaylive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thisdaylive.com Daily Mail and Mail on Sunday newspapers.
The International Society of Addiction Medicine (ISAM) is a very prestigious association that knows its origin since 1998. Addiction has many related issues ass
Image
Dr. Silvia Cruz
Silvia Cruz, Ph.D., is an international expert on the neurobiology of addiction who was a 1996-1997 NIDA INVEST Fellow at Virginia Commonwealth University (VCU) with Robert Balster, Ph.D. In 2010, she spent a year as an invited researcher at Mexico’s
Ramón de la Fuente Muñiz National Institute of Psychiatry
, where she focused on epidemiology, anthropology, and sociology. Dr. Cruz is currently a full professor at Mexico’s Center of Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), where she previously served as graduate program coordinator and chair of the Department of Pharmacobiology. This interview is based on her webinar for the International Society of Addiction Medicine (ISAM) Neuroscience Interest Group series, “In Love with Addiction Neuroscience.”